PKLR and hypersensitivity reaction disease: In summary, our results demonstrated a regulatory mechanism that inhibition of AR signaling in hormone-sensitive PCa through ADT may cause a reduction in ZBTB10, leading to abundances of PKLR-promoting oncogenic signaling pathway components in a subset of patients with hormone-refractory PCa associated with enhanced glucose metabolism and NE characteristics.